Gastric Carcinoma with low ROR alpha, low E- Cadherin and High LAPTM4B Immunohistochemical Profile; is associated with unfavorable prognosis in Egyptian patients

References

• Zeeneldin, A. A.; Ramadan, H.; El Gammal, M. M.; Saber, M. M.; Elgamal, D.; Sherisher, M. A. Gastric Carcinoma at Tanta Cancer Center: A Comparative Retrospective Clinico-Pathological Study of the Elderly versus the Non-Elderly. J. Egypt. Natl. Canc. Inst. 2014, 26(3), 127–137. DOI: 10.1016/j.jnci.2014.04.002.
   PubMedGoogle Scholar
• Mokhtar, N.; Salama, A.; Badawy, O.; Khorshed, E.; Mohamed, G.; Ibrahim, M.; Abdelazim, H. Cancer Pathology Registry a 12 Year Registry (2000-2011). Cairo University, National Cancer Institute. Pathol. Department. 2016, 13, 192–208.
   Google Scholar
• Leiting, J. L.; Grotz, T. E. Advancements and Challenges in Treating Advanced Gastric Cancer in the West. World J. Gastrointest Oncol. 2019, 11(9), 652–664. DOI: 10.4251/wjgo.v11.i9.652.
   PubMed Web of Science ®Google Scholar
• Chen, Z. D.; Zhang, P.; Xi, H. Q.; Wei, B.; Chen, L.; Tang, Y. Recent Advances in the Diagnosis, Staging, Treatment, and Prognosis of Advanced Gastric Cancer: A Literature Review. Front. Med. 2021, 8, 8. DOI: 10.3389/fmed.2021.744839.
   Web of Science ®Google Scholar
• Tan, P. H.; Ellis, I.; Allison, K.; Brogi, E.; Fox, S. B.; Lakhani, S.; Lazar, A. J.; Morris, E. A.; Sahin, A.; Salgado, R., et al. The 2019 World Health Organization Classification of Tumours of the Breast. Histopathology. 2020, 77(2), 181–185.
   PubMed Web of Science ®Google Scholar
• Molaei, F.; Forghanifard, M. M.; Fahim, Y.; Abbaszadegan, M. R. Molecular Signaling in Tumorigenesis of Gastric Cancer. Iran. Biomed. J. 2018, 22(4), 217. DOI: 10.29252/ibj.22.4.217.
   PubMedGoogle Scholar
• Correa, P.; Houghton, J. Carcinogenesis of Helicobacter pylori. Gastroenterol. 2007, 133(2), 659–672. DOI: 10.1053/j.gastro.2007.06.026.
   PubMed Web of Science ®Google Scholar
• Molina-Castro, S. E.; Tiffon, C.; Giraud, J.; Boeuf, H.’ Sifr, E.; Giese, A.; Belleannée, G.; Lehours, P.; Bessède, E.; Mégraud, F., Dubus, P.; et al. The Hippo Kinase LATS2 Controls Helicobacter pylori-Induced Epithelial-Mesenchymal Transition and Intestinal Metaplasia in Gastric Mucosa. Cell. Mol. Gastroenterol. Hepatol. 2020, 9(2), 257–276.
   PubMed Web of Science ®Google Scholar
• Du, J.; Xu, R. RORα, a Potential Tumor Suppressor and Therapeutic Target of Breast Cancer. Int. J. Mol. Sci. 2012, 13(12), 15755–15766. DOI: 10.3390/ijms131215755.
   PubMed Web of Science ®Google Scholar
• Zhu, Y.; McAvoy, S.; Kuhn, R.; Smith, D. RORA, a Large Common Fragile Site Gene, is Involved in Cellular Stress Response. Oncogene. 2006, 25(20), 2901–2908. DOI: 10.1038/sj.onc.1209314.
   PubMed Web of Science ®Google Scholar
• Rehman, Z.; Fahim, A.; Bhatti, A.; Sadia, H.; John, P. Co-Expression of HIF-1α, MDR1 and LAPTM4B in Peripheral Blood of Solid Tumors. PeerJ. 2019, 7, e6309. DOI: 10.7717/peerj.6309.
   PubMed Web of Science ®Google Scholar
• Wang, F.; Wu, H.; Zhang, S.; Lu, J.; Lu, Y.; Zhan, P.; Fang, Q.; Wang, F.; Zhang, X.; Xie, C., et al. LAPTM4B facilitates tumor growth and induces autophagy in hepatocellular carcinoma. Cancer Manag. Res. 2019, 11, 2485. DOI: 10.2147/CMAR.S201092.
   PubMed Web of Science ®Google Scholar
• Wang, L.; Meng, Y.; Zhang, Q. Y. LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR. BMC Cancer 2019 , 19, 1–14. DOI: 10.1186/s12885-019-5506-7.
   PubMed Web of Science ®Google Scholar
• Yilmaz, M.; Christofori, G. EMT, the Cytoskeleton, and Cancer Cell Invasion. Cancer Metastasis. Rev. 2009, 28(1–2), 15–33. DOI: 10.1007/s10555-008-9169-0.
   PubMed Web of Science ®Google Scholar
• Graziano, F. The E-Cadherin Gene, Structure and Function. In Spotlight on Familial and Hereditary Gastric Cancer; Corso, G. Roviello, F., Eds.; Springer Netherlands: Dordrecht, 2013; pp. 27–33.
   Google Scholar
• Wong, S. M.; Fang, C. M.; Chuah, L. H.; Leong, C. O.; Ngai, S. C. E-Cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit. Rev. Oncol. Hematol. 2018, 121, 11–22. DOI: 10.1016/j.critrevonc.2017.11.010.
   PubMed Web of Science ®Google Scholar
• Jeanes, A.; Gottardi, C.; Yap, A. Cadherins and Cancer: How Does Cadherin Dysfunction Promote Tumor Progression? Oncogene. 2008, 27(55), 6920–6929. DOI: 10.1038/onc.2008.343.
   PubMed Web of Science ®Google Scholar
• Carrasco, G.; Corvalan, A. H. Helicobacter pylori-Induced Chronic Gastritis and Assessing Risks for Gastric Cancer. Gastroenterol. Res. Pract. 2013, 2013, 1–8. DOI: 10.1155/2013/393015.
   Web of Science ®Google Scholar
• Dixon, M. F.; Genta, R. M.; Yardley, J. H.; Correa, P. Classification and Grading of Gastritis: The Updated Sydney System. Am. J. Surg. Pathol. 1996, 20(10), 1161–1181. DOI: 10.1097/00000478-199610000-00001.
   PubMed Web of Science ®Google Scholar
• Nagtegaal, I. D.; Odze, R. D.; Klimstra, D.; Paradis, V.; Rugge, M.; Schirmacher, P.; Washington, K. M.; Carneiro, F.; Cree, I. A. WHO Classification of Tumours Editorial Board. The 2019 WHO Classification of Tumours of the Digestive System. Histopathology. 2020, 76(2), 182–188. DOI: 10.1111/his.13975.
   PubMed Web of Science ®Google Scholar
• CAP CoAP. Protocol for the Examination of Specimens from Patients with Carcinoma of the Stomach. https://documents.cap.org/protocols/cp-giupper-stomach-20-41002020 https://documents.cap.org/protocols/cp-giupper-stomach-20-4100 ( accessed oct 9th 2020).
   Google Scholar
• Amin, M. B.; Greene, F. L.; Edge, S. B.; Compton, C. C.; Gershenwald, J. E.; Brookland, R. K.; Meyer, L.; Gress, D. M.; Byrd, D. R.; Winchester, D. P., et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge from a Population-Based to a More “Personalized” Approach to Cancer Staging. CA Cancer J. Clin. 2017, 67(2), 93–99.
   PubMed Web of Science ®Google Scholar
• Laurén, P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal- Type Carcinoma: An Attempt at a Histo-Clinical Classification. Acta pathologica et microbiologica Scandinavica. 1965, 64(1), 31–49. DOI: 10.1111/apm.1965.64.1.31.
   PubMedGoogle Scholar
• Inoue, K.; Nakane, Y.; Michiura, T.; Nakai, K.; Iiyama, H.; Sato, M.; Okumura, S.; Yamamichi, K.; Hioki, K. Histopathological Grading Does Not Affect Survival After R0 Surgery for Gastric Cancer. Eur. J. Surg. Oncol. 2002, 28(6), 633–636. DOI: 10.1053/ejso.2002.1310.
   PubMedGoogle Scholar
• Lohneis, P.; Hieggelke, L.; Gebauer, F.; Ball, M.; Bruns, C.; Buettner, R.; Löser, H.; Quaas, A. Tumor Budding Assessed According to the Criteria of the International Tumor Budding Consensus Conference Determines Prognosis in Resected Esophageal Adenocarcinoma. Virchows Archiv. 2021, 478(3), 393–400. DOI: 10.1007/s00428-020-02897-3.
   PubMed Web of Science ®Google Scholar
• Fuchs, T. L.; Sioson, L.; Sheen, A.; Jafari-Nejad, K.; Renaud, C. J.; Andrici, J.; Ahadi, M.; Chou, A.; Gill, A. J. Assessment of Tumor-Infiltrating Lymphocytes Using International TILs Working Group (ITWG) System is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients. Am. J. Surg. Pathol. 2020, 44(4), 536–544. DOI: 10.1097/PAS.0000000000001409.
   PubMed Web of Science ®Google Scholar
• Bankhead, P.; Fernández, J. A.; McArt, D. G.; Boyle, D. P.; Li, G.; Loughrey, M. B.; Irwin, G. W.; Harkin, D. P.; James, J. A.; McQuaid, S., et al. Integrated Tumor Identification and Automated Scoring Minimizes Pathologist Involvement and Provides New Insights to Key Biomarkers in Breast Cancer. Lab. Invest. 2018, 98(1), 15–26.
   PubMed Web of Science ®Google Scholar
• Liu, J.; Xu, B.; Zheng, C.; Gong, Y.; Garibaldi, J.; Soria, D.; Green, A.; Ellis, I. O.; Zou, W.; Qiu, G. An End-To-End Deep Learning Histochemical Scoring System for Breast Cancer Tissue Microarray. IEEE Trans. Med. Imaging. 2019, 38(2), 617–628. DOI: 10.1109/TMI.2018.2868333.
   PubMed Web of Science ®Google Scholar
• Zhang, H.; Wei, Q.; Liu, R.; Qi, S.; Liang, P.; Qi, C.; Wang, A.; Sheng, B.; Li, L.; Xu, Y., et al. Overexpression of Laptm4B-35: A Novel Marker of Poor Prognosis of Prostate Cancer. PLoS. One. 2014, 9(3), e91069. DOI: 10.1371/journal.pone.0091069.
   PubMed Web of Science ®Google Scholar
• Sisodiya, N.; Rajat, J. Clinicopathological significance of E-Cadherin immunoexpression in gastric carcinoma. Int. J. Contemp. Med. Res 2016, 3, 2431–2433.
   Google Scholar
• Sadanandan, A.; A, C. E-cadherin Immunohistochemical Expression in Gastric Carcinoma. Int. J. Contemp. Med. Res. 2020, 7(1), A9–13. DOI: 10.21276/ijcmr.2020.7.1.7.
   Google Scholar
• Prathipaa, R.; Divya, J. E-Cadherin Expression Significance in Gastric Carcinoma. Panacea. J. Med. Sci. 2023, 13(2), 418–422. DOI: 10.18231/j.pjms.2023.079.
   Google Scholar
• Wang, Z.; Xiong, F.; Wang, X.; Qi, Y.; Yu, H.; Zhu, Y.; Zhu, H. Nuclear Receptor Retinoid-Related Orphan Receptor Alpha Promotes Apoptosis but is Reduced in Human Gastric Cancer. Oncotarget. 2017, 8(7), 11105. DOI: 10.18632/oncotarget.14364.
   PubMedGoogle Scholar
• Su, J.; Su, B.; Xia, H.; Liu, F.; Zhao, X.; Li, J.; Zhang, J.; Shi, Y.; Zeng, Y.; Zeng, X., et al. RORα Suppresses Epithelial-To-Mesenchymal Transition and Invasion in Human Gastric Cancer Cells via the Wnt/β-Catenin Pathway. Front. Oncol. 2019, 9, 06–9. DOI: 10.3389/fonc.2019.01344.
   PubMed Web of Science ®Google Scholar
• Fu, R. D.; Qiu, C.-H.; Chen, H. A.; Zhang, Z. G.; Lu, M. Q. Retinoic acid receptor-related receptor alpha (RORalpha) is a prognostic marker for hepatocellular carcinoma. Tumour Biol. 2014 , 35(), 7603–7610. DOI: 10.1007/s13277-014-2007-9.
   PubMedGoogle Scholar
• Brożyna, A. A.; Jóźwicki, W.; Skobowiat, C.; Jetten, A.; Slominski, A. T. RORα and RORγ Expression Inversely Correlates with Human Melanoma Progression. Oncotarget. 2016, 7(39), 63261. DOI: 10.18632/oncotarget.11211.
   PubMedGoogle Scholar
• Kano, H.; Takayama, T.; Midorikawa, Y.; Nagase, H. Promoter Hypomethylation of RAR-Related Orphan Receptor α 1 is Correlated with Unfavorable Clinicopathological Features in Patients with Colorectal Cancer. Biosci. Trends. 2016, 10(3), 202–209. DOI: 10.5582/bst.2016.01097.
   PubMed Web of Science ®Google Scholar
• Ulase, D.; Heckl, S.; Behrens, H. M.; Krüger, S.; Röcken, C. Prognostic Significance of Tumour Budding Assessed in Gastric Carcinoma According to the Criteria of the International Tumour Budding Consensus Conference. Histopathology. 2020, 76(3), 433–446. DOI: 10.1111/his.13997.
   PubMed Web of Science ®Google Scholar
• Zhou, S.; Chen, H.; Yuan, P.; Shi, N.; Wang, X.; Hu, J.; Liu, L. Helicobacter pylori Infection Promotes Epithelial-To-Mesenchymal Transition of Gastric Cells by Upregulating LAPTM4B. Biochem. Biophys. Res. Commun. 2019, 514(3), 893–900. DOI: 10.1016/j.bbrc.2019.05.036.
   PubMed Web of Science ®Google Scholar
• Liu, L.; Xu, X.; Jing, L.; Zhou, G.; Cao, Z.; Han, Y.; Zhou, R.; Deng, D. Lysosomal-Associated Protein Transmembrane 4 Beta-35 Overexpression is a Novel Independent Prognostic Marker for Gastric Carcinoma. PLoS. One. 2015, 10(2), e0118026. DOI: 10.1371/journal.pone.0118026.
   PubMed Web of Science ®Google Scholar
• Xiao, M.; Ji, S.; Wang, H.; Wang, J.; Huang, Y.; Li, Z. Overexpression of LAPTM4B: An Independent Prognostic Marker in Breast Cancer. J. Cancer Res. Clin. Oncol. 2013, 139(4), 661–667. DOI: 10.1007/s00432-012-1368-y.
   PubMed Web of Science ®Google Scholar
• Zhou, L.; He, X. D.; Yu, J. C.; Zhou, R. L.; Shan, Y.; Rui, J. A. Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells. Surgery. 2011, 150(1), 25–31. DOI: 10.1016/j.surg.2010.12.010.
   PubMed Web of Science ®Google Scholar
• Li, Y.; Zou, L.; Li, Q.; Haibe- Kains, B.; Tian, R.; Li, Y.; Desmedt, C.; Sotiriou, C.; Szallasi, Z.; Iglehart, J. D., et al. Amplification of LAPTM4B and YWHAZ Contributes to Chemotherapy Resistance and Recurrence of Breast Cancer. Nat. Med. 2010, 16(2), 214–218.
   PubMed Web of Science ®Google Scholar
• Jung, H. J.; Hong, S. J.; Kim, S. H. Immunohistochemical Expression of Epithelial-Mesenchymal Transition Markers in Early Gastric Cancer: Cancer Tissue versus Noncancer Tissue. Clin. Endosc. 2019, 52(5), 464. DOI: 10.5946/ce.2018.181.
   PubMed Web of Science ®Google Scholar
• Sun, G. Y.; Wu, J. X.; Wu, J. S.; Pan, Y.; Jin, R. C. 1. Caveolin-1, E-Cadherin and β-Catenin in Gastric Carcinoma, Precancerous Tissues and Chronic Non-Atrophic Gastritis. Chin. J. Cancer Res. 2012, 24(1), 23–28. DOI: 10.1007/s11670-012-0023-0.
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo, M.; Pietrantonio, F.; Pellegrinelli, A.; Martinetti, A.; Mariani, L.; Daidone, M. G.; Bajetta, E.; Pelosi, G.; de Braud, F.; Floriani, I., et al. Osteopontin, E-Cadherin, and β-Catenin Expression as Prognostic Biomarkers in Patients with Radically Resected Gastric Cancer. Gastric. Cancer. 2016, 19(2), 412–420.
   PubMed Web of Science ®Google Scholar
• Nakagawa, Y.; Ohira, M.; Kubo, N.; Yamashita, Y.; Sakurai, K.; Toyokawa, T.; Tanaka, H.; Muguruma, K.; Shibutani, M.; Yamazoe, S., et al. Tumor Budding and E-Cadherin Expression are Useful Predictors of Nodal Involvement in T1 Esophageal Squamous Cell Carcinoma. Anticancer. Res. 2013, 33(11), 5023–5029.
   PubMed Web of Science ®Google Scholar
• Zeisberg, M.; Neilson, E. G. Biomarkers for Epithelial-Mesenchymal Transitions. J. Clin. Invest. 2009, 119(6), 1429–1437. DOI: 10.1172/JCI36183.
   PubMed Web of Science ®Google Scholar
• Wang, C.; Huang, H.; Huang, Z.; Wang, A.; Chen, X.; Huang, L.; Zhou, X.; Liu, X. Tumor Budding Correlates with Poor Prognosis and Epithelial-Mesenchymal Transition in Tongue Squamous Cell Carcinoma. J. Oral Pathol. Med. 2011, 40(7), 545–551. DOI: 10.1111/j.1600-0714.2011.01041.x.
   PubMed Web of Science ®Google Scholar
• Min, X.; Shanshan, Y.; FanLing, M.; Yu, Q.; Yue, Y.; Shusheng, J.; XiuMing, C.; Changli, L.; Xiaoming, N.; Yuanxi, H. LAPTM4B Predicts Axillary Lymph Node Metastasis in Breast Cancer and Promotes Breast Cancer Cell Aggressiveness in vitro. Cell Physiol. Biochem. 2017, 41(3), 1072–1082. DOI: 10.1159/000464115.
   PubMedGoogle Scholar
• Kim, J.-Y.; Han, J.-H.; Park, G.; Seo, Y.-W.; Yun, C.-W.; Lee, B.-C.; Bae, J.; Moon, A. R.; Kim, T.-H. Correction: Necrosis-Inducing Peptide Has the Beneficial Effect on Killing Tumor Cells Through Neuropilin (NRP-1) Targeting. Oncotarget. 2018, 9(42), 26977. DOI: 10.18632/oncotarget.25604.
   PubMedGoogle Scholar
• Roberto, M.; Botticelli, A.; Strigari, L.; Ghidini, M.; Onesti, C. E.; Ratti, M.; Benzoni, I.; Pizzo, C.; Falcone, R.; Lomiento, D., et al. Prognosis of Elderly Gastric Cancer Patients After Surgery: A Nomogram to Predict Survival. Med. Oncol 2018. 2018, 35(7), 1–9.
   Google Scholar
• Smith, B. R.; Stabile, B. E. Extreme Aggressiveness and Lethality of Gastric Adenocarcinoma in the Very Young. Arch. Surg. 2009, 144(6), 506–510. DOI: 10.1001/archsurg.2009.77.
   PubMedGoogle Scholar
• Isobe, T.; Hashimoto, K.; Kizaki, J.; Miyagi, M.; Aoyagi, K.; Koufuji, K.; Benzoni, I.; Pizzo, C.; Falcone, R.; Lomiento, D., et al. Characteristics and Prognosis of Gastric Cancer in Young Patients. Oncol. Rep. 2013, 30(1), 43–49.
   PubMed Web of Science ®Google Scholar
• Song, P.; Wu, L.; Jiang, B.; Liu, Z.; Cao, K.; Guan, W. Age-Specific Effects on the Prognosis After Surgery for Gastric Cancer: A SEER Population-Based Analysis. Oncotarget. 2016, 7(30), 48614. DOI: 10.18632/oncotarget.9548.
   PubMedGoogle Scholar
• Lee, J. G.; Kim, S. A.; Eun, C. S.; Han, D. S.; Kim, Y. S.; Choi, B. Y.; Song, K. S.; Kim, H. J.; Park, C. H.; Katoh, M. Impact of Age on Stage-Specific Mortality in Patients with Gastric Cancer: A Long-Term Prospective Cohort Study. PLoS. One. 2019, 14(8), e0220660. DOI: 10.1371/journal.pone.0220660.
   PubMed Web of Science ®Google Scholar
• Wang, X.; Jia, R.; Chen, K.; Wang, J.; Jiang, K.; Wang, Z. RORα and REV-ERBα are Associated with Clinicopathological Parameters and are Independent Biomarkers of Prognosis in Gastric Cancer. Technol. Cancer Res. Treat. 2021, 20, 15330338211039670. DOI: 10.1177/15330338211039670.
   Web of Science ®Google Scholar
• Xiong, G.; Wang, C.; Evers, B. M.; Zhou, B. P.; Xu, R. RORα Suppresses Breast Tumor Invasion by Inducing SEMA3F Expression. Cancer Res. 2012, 72(7), 1728–1739. DOI: 10.1158/0008-5472.CAN-11-2762.
   PubMed Web of Science ®Google Scholar
• Li, X.; Song, C.; Wang, K.; Li, N.; Sun, S.; Li, N.; Zhao, Z.; Li, M. Prognostic Significance of LAPTM4B and p27kip1 Expression in Triple-Negative Breast Cancer. Cancer Biomark. 2019, 25(1), 19–27. DOI: 10.3233/CBM-182094.
   PubMed Web of Science ®Google Scholar
• Su, Q.; Luo, H.; Zhang, M.; Gao, L.; Zhao, F. LAPTM4B Promotes the Progression of Nasopharyngeal Cancer. Bosn. J. Basic Med. Sci. 2021, 21(3), 305. DOI: 10.17305/bjbms.2020.4738.
   PubMed Web of Science ®Google Scholar
• Kotowski, U.; Kadletz, L.; Schneider, S.; Oberndorfer, F.; Schnoell, J.; Gurnhofer, E.; Kenner, L.; Lucas, T.; Heiduschka, G. Overexpression of Laptm4B-35 is a Negative Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Sci. Rep. 2019, 9(1), 1–8. DOI: 10.1038/s41598-019-55319-z.
   PubMedGoogle Scholar
• Liu, X.; Chu, K. M. E-Cadherin and Gastric Cancer: Cause, Consequence, and Applications. Biomed Res. Int. 2014, 2014, 1–9. DOI: 10.1155/2014/637308.
   Web of Science ®Google Scholar
• Lau, M. T.; So, W. K.; Leung, P. C. K.; Migliaccio, A. Fibroblast Growth Factor 2 Induces E-Cadherin Down-Regulation via PI3K/Akt/mTOR and MAPK/ERK Signaling in Ovarian Cancer Cells. PLoS. One. 2013, 8(3), e59083. DOI: 10.1371/journal.pone.0059083.
   PubMed Web of Science ®Google Scholar
• Mohamed, A. S.; Aiad, H. A.; Kandil, M. A.; Asaad, N. Y.; El Tahmodi, M. A.; Dawoud, M. M.; Hemida, A. S. Immunohistochemical Evaluation of the Epithelial–Mesenchymal Transition Profile: Twist, E-Cadherin, and Vimentin in Colorectal Carcinoma. Egypt. J Pathol. 2018, 38(1), 97–104. DOI: 10.1097/01.XEJ.0000542231.60893.00.
   Google Scholar